지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.9
- 수록면
- 243 - 252 (10page)
- DOI
- 10.17998/jlc.2024.05.26
이용수
초록· 키워드
오류제보하기
Backgrounds/Aims: Systemic therapy is the current standard treatment for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, some patients with HCC and EHM undergo transarterial chemoembolization (TACE) to manage intrahepatic tumors. Herein, we aimed to explore the appropriateness of TACE in patients with HCC and EHM in an era of advanced systemic therapy.
Methods: This study analyzed 248 consecutive patients with HCC and EHM (median age, 58.5 years; male, 83.5%; Child-Pugh A, 88.7%) who received TACE or systemic therapy (83 sorafenib, 49 lenvatinib, 28 immunotherapy-based) between January 2018 and January 2021.
Results: Among the patients, 196 deaths were recorded during a median follow-up of 8.9 months. Patients who received systemic therapy had a higher albumin-bilirubin grade, elevated tumor markers, an increased number of intrahepatic tumors, larger-sized tumors, and more frequent portal vein invasion than those who underwent TACE. TACE was associated with longer median overall survival (OS) than sorafenib (15.1 vs. 4.7 months; 95% confidence interval [CI], 11.1-22.2 vs. 3.7-7.3; hazard ratio [HR], 1.97; P<0.001). After adjustment for potential confounders, TACE was associated with statistically similar survival outcomes to those of lenvatinib (median OS, 8.0 months; 95% CI, 6.5-11.0; HR, 1.21; P=0.411) and immunotherapies (median OS, 14.3 months; 95% CI, 9.5-27.0; HR, 1.01; P=0.973), demonstrating survival benefits equivalent to these treatments.
Conclusions: In patients with HCC and EHM, TACE can provide a survival benefit comparable to that of newer systemic therapies. Accordingly, TACE remains a valuable option in this era of new systemic therapies.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Clinical and Molecular Hepatology
2020 .01
-
Current role of systemic therapy in transarterial chemotherapy-refractory hepatocellular carcinoma patients
International Journal of Gastrointestinal Intervention
2021 .10
-
The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
Clinical and Molecular Hepatology
2017 .01
-
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Clinical and Molecular Hepatology
2021 .01
-
Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observational studies
Annals of Hepato-Biliary-Pancreatic Surgery
2020 .08
-
Ruptured Massive Hepatocellular Carcinoma Cured by Transarterial Chemoembolization
Journal of Liver Cancer
2020 .01
-
Efficacy of Transarterial Chemoembolization Combined with Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Transcatheter Arterial Chemoembolization Combined with Interferon-α is Safe and Effective for Patients with Hepatocellular Carcinoma after Curative Resection
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery
Journal of Liver Cancer
2020 .01
-
Effect of neoadjuvant transarterial chemoembolization followed by resection versus upfront liver resection on the survival of single large hepatocellular carcinoma patients: A systematic review and meta-analysis
Annals of Hepato-Biliary-Pancreatic Surgery
2024 .08
-
Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
Journal of Liver Cancer
2023 .03
-
Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
Clinical and Molecular Hepatology
2018 .01
-
Rare Case of Pyogenic Brain Abscess after Transarterial Chemoembolization in a Patient with Hepatocellular Carcinoma: Case Report and Literature Review
Journal of Liver Cancer
2021 .01
-
Clinical usefulness of transarterial chemoembolization response prior to liver transplantation as predictor of optimal timing for living donor liver transplantation
Annals of Surgical Treatment and Research
2018 .08
-
Rupture of hepatocellular carcinoma after transcatheter arterial chemoembolization: A case report
International Journal of Gastrointestinal Intervention
2021 .01
-
Outcomes of liver resection and transarterial chemoembolization in patients with multinodular BCLC-A hepatocellular carcinoma
Journal of Liver Cancer
2024 .09
-
Transarterial Chemoembolization Monotherapy in Combination with Radiofrequency Ablation or Percutaneous Ethanol Injection for Hepatocellular Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: History, background, and the roles
International Journal of Gastrointestinal Intervention
2020 .01
-
Transarterial chemoembolization versus resection for the intermediate stage hepatocellular carcinoma
Clinical and Molecular Hepatology
2016 .01
-
Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
Yonsei Medical Journal
2021 .01
최근 본 자료
댓글(0)
0